New Partnership Aims To Advance Prostate Cancer Care: NorthStar and Convergent Expand Collaboration

NorthStar Medical Radioisotopes and Convergent Therapeutics are enhancing their collaboration to advance the treatment of prostate cancer with their innovative drug, CONV01-α. This promising new therapy features a monoclonal antibody that targets the prostate-specific membrane antigen and is combined with Ac-225, a potent radioactive element.

Under the new agreement, NorthStar will provide Convergent with high-purity, environmentally friendly non-carrier-added Ac-225. This crucial component will be integral to the development of CONV01-α. Additionally, NorthStar will spearhead further research and development efforts, aiming to unlock new advancements for CONV01-α and explore additional opportunities within Convergent's portfolio.

Frank Scholz, CEO of NorthStar Medical Radioisotopes, said in a statement, “At NorthStar, our passion is to reduce technological and operational barriers to help companies like Convergent Therapeutics not only secure a reliable source of Ac-225 but manufacture a finished, patient-ready drug product and continue to develop new and additional therapeutic indications for the patients who need new and better medicines. We are proud to be supporting Convergent and look forward to working with them to help make new medicines like CONV01-a therapeutic reality.”

Convergent Therapeutics has secured FDA approval for its investigational new drug application for CONV01-α, marking a significant milestone in the development of its prostate cancer treatment. With this clearance, the company can now advance to Phase II clinical trials, expanding the scope of its research into CONV01-α.

The drug leverages Ac-225, an alpha-emitting radionuclide designed to target and destroy cancer cells by inducing double-strand DNA breaks. The localized nature of alpha particles minimizes damage to adjacent healthy cells, enhancing the therapy's safety profile. While the current focus is on prostate cancer, CONV01-α has the potential for broader applications in treating various cancer types in the future.